August 14, 2025
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
August 7, 2025
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
May 9, 2025
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
February 27, 2025
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
December 6, 2024
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
November 7, 2024
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
October 22, 2024
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
September 17, 2024
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
September 3, 2024
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
Displaying 11 - 20 of 154